glp-1 wegovy Arrival of weight-loss pill new headache for food makers Ro Launches Wegovy® Pill Through

Description

Shaman AM, Bain SC, Bakris GL, Buse JB, Idorn T, Mahaffey KW, et al

Debunking GLP-1 Myths: The Truth About Medical Weight Loss

Adjusting for age, sex, race/ethnicity, income, education, and food security status, individuals experiencing nutrition insecurity were 4060 % more likely to have obesity as well as type 2 diabetes, heart disease, hypertension, and hypercholesterolemia

The association between glucose-dependent insulinotropic polypeptide and/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: A real-world data analysis

Emerging areas for more study include dietary modulation of endogenous GLP-1, strategies to improve compliance, nutritional priorities for weight maintenance post-cessation, combination or staged intensive lifestyle management, and diagnostic criteria for clinical obesity